Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIS410
- Development stage
- Phase 2
- Lead developer
- Visterra
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
VIS410 is a fully human IgG1 monoclonal antibody developed to broadly neutralize all known strains of influenza A virus. It binds to a conserved epitope on the stem region of the hemagglutinin (HA) protein, preventing the conformational changes required for viral fusion with host cell membranes and thereby inhibiting viral replication. The drug was designed as a single-dose intravenous therapy for hospitalized patients with influenza A and demonstrated efficacy in reducing symptom duration and viral load in clinical studies. Developed by Visterra, it reached Phase 2 clinical trials but development was discontinued for strategic reasons[1][3][4][6][7].
- Other names
- IMMUNOGLOBULIN G1, ANTI-(INFLUENZA HEMAGGLUTININ) (HUMAN MONOCLONAL VIS410 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL VIS410 .KAPPA.-CHAIN, DIMER
02
Targets
HA stem (Influenza A hemagglutinin stem region)
Beyond the preview
Go deeper on VIS410.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIS410.